Targeting Hypertension With a New Adenosine Triphosphate–sensitive Potassium Channel Opener Iptakalim
Authors:
- JingHui HuangJHJingHui Huang
- WenYu CuiWCWenYu Cui
- ChaoLiang LongCLChaoLiang Long
- YanFang ZhangYZYanFang Zhang
- Hai WangHWHai Wang
- 1 September 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (3) , 215-228
Abstract
Hypertension is the most common cardiovascular disease. The discovery of the antihypertensive action of adenosine triphosphate-sensitive potassium (KATP) channel openers was a significant advance in the treatment of hypertension. Iptakalim is a novel KATP channel opener with a unique chemical structure that differs from other KATP openers. Among the 3 different subtypes of KATP channels heterologously expressed in human embryonic kidney cells and Xenopus oocytes, iptakalim exhibits significant selectivity for SUR2B/Kir6.1 channels, mild effects on SUR2A/Kir6.2 channels, and fails to open SUR1/Kir6.2 channels. Iptakalim is a more potent activator of the SUR2B/Kir6.1 subtype of KATP channels than diazoxide and pinacidil, the 2 most commonly studied KATP channel openers. Iptakalim selectively produces arteriolar vasodilation with essentially no effect on the capacitance vessels. It can preferentially relax arterioles and small arteries, without affecting large arteries. Furthermore, iptakalim strongly lowers the blood pressure of hypertensive rodents and humans but has little effect on normotensive rodents and humans. Selective antihypertensive action is not observed with pinacidil or diazoxide and may be due to the high selectivity of iptakalim for the SUR2B/Kir6.1 subtype of KATP channels, as well as its selective relaxation of resistance vessels. In pulmonary arterial smooth muscle cells, iptakalim inhibits the increase of cytoplasmic free Ca2+ concentration, as well as cell proliferation induced by endothelin-1. Furthermore, iptakalim has exerted protective effects against hypertensive damage to target organs in rats and improves endothelial dysfunction associated with cardiovascular diseases by selective activation of the SUR2B/Kir6.1 subtype of KATP channels expressed in the endothelium. Clinical trials of iptakalim in the treatment of mild-moderate hypertension have been completed in China. In additional to strong antihypertensive efficacy, iptakalim seems to have a favorable safety and tolerability profile. Iptakalim is a promising new generation antihypertensive drug.Keywords
This publication has 37 references indexed in Scilit:
- KATP channels as molecular sensors of cellular metabolismNature, 2006
- KATP channel: relation with cell metabolism and role in the cardiovascular systemThe International Journal of Biochemistry & Cell Biology, 2005
- Molecular basis and characteristics of KATP channel in human corporal smooth muscle cellsInternational Journal Of Impotence Research, 2003
- Molecular basis of ATP-sensitive K+ channels in rat vascular smooth musclesBiochemical and Biophysical Research Communications, 2002
- K+ channels as therapeutic drug targetsPharmacology & Therapeutics, 2002
- Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system and K+ channel openersPharmacology & Therapeutics, 2000
- Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamideProceedings of the National Academy of Sciences, 1999
- Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea‐sensitive but ATP‐insensitive K+ channel.The Journal of Physiology, 1997
- Two types of ATP‐sensitive potassium channels in rat portal vein smooth muscle cellsBritish Journal of Pharmacology, 1996
- Hyperpolarizing Vasodilators Activate ATP-sensitive K + Channels in Arterial Smooth MuscleScience, 1989